Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Cervical microbiome

ABSTRACT: 16S rDNA full-length assembly sequencing technology analysis of cervical microbiome of IVF Patients

PROVIDER: PRJNA1224408 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR32489100.fastq.gz	Fastqsanger.gz
	SRR32489200.fastq.gz	Fastqsanger.gz
	SRR32489101.fastq.gz	Fastqsanger.gz
	SRR32489201.fastq.gz	Fastqsanger.gz
	SRR32489102.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 131

Similar Datasets

Project description:16S rDNA full-length assembly sequencing technology analysis of cervical microbiome of IVF Patients

| PRJNA903403 | ENA

Proteomics of cervical mucus in natural and stimulated cycle

Project description:Cervical mucus is a viscous fluid functioning as a uterine cervix plug. It is formed and produced by cervical glands located in the cervix. During ovulation, cervical mucus starts to become less viscous, which is a good window for non-invasive sampling. Our study focuses on the proteomic characterization of cervical mucus, which may thus act as a non-invasively acquired source of biomarkers for diseases and physiological conditions of the female genital tract. Our study aimed at two aims - the first is to optimize a proteomic workflow of cervical mucus processing. The second aim is to assess differences in the proteomic composition of cervical mucus in natural ovulatory cycles and IVF cycles with controlled ovarian hyperstimulation. The sampling was done in cooperation with women undergoing intrauterine insemination in a natural ovulatory cycle and women undergoing controlled ovarian hyperstimulation for IVF. The optimization of proteomic workflow including an analysis on an Orbitrap mass spectrometer was performed. The results revealed the protein composition and the differences of the cervical mucus between natural and stimulated uterus.

2023-03-10 | PXD037654 | Pride

GNPS Comparable plasma lipid changes in patients with high-grade cervical intraepithelial neoplasia and patients with cervical cancer

Project description:Comparable plasma lipid changes in patients with high-grade cervical intraepithelial neoplasia and patients with cervical cancer

2020-10-22 | MSV000086351 | GNPS

Project description:16S rDNA full-length assembly sequencing technology analysis of intestinal microbiome of PCOS and control

| PRJNA694729 | ENA

Project description:16S rDNA amplicon full-length sequencing in rhizosphere soil

| PRJNA1108430 | ENA

Meta-omics analysis indicates the saliva microbiome and its proteins associated with the prognosis of oral cancer patients

Project description:The relationship between the microbial changes with clinical-pathological outcomes are still far from being conclusive. Herein, we investigate the ability of metagenomics (MG) and metaproteomics (MP) saliva data in distinguishing C, L0 and L1 patients. For that, we combined two strategies using MG analysis using 16S rDNA sequencing of saliva cells, and MP analysis using liquid chromatography tandem mass spectrometry of saliva supernatant and cells.

2022-11-09 | PXD022859 | Pride

Azithromycin effects on lung microbiome in COPD patient

Project description:Azithromycin (AZM) reduces pulmonary inflammation and exacerbations in chronic obstructive pulmonary disease patients with emphysema. The antimicrobial effects of AZM on the lung microbiome are not known and may contribute to its beneficial effects. Methods. Twenty smokers with emphysema were randomized to receive AZM 250 mg or placebo daily for 8 weeks. Bronchoalveolar lavage (BAL) was performed at baseline and after treatment. Measurements included: rDNA gene quantity and sequence. Results. Compared with placebo, AZM did not alter bacterial burden but reduced Î±-diversity, decreasing 11 low abundance taxa, none of which are classical pulmonary pathogens. Conclusions. AZM treatment the lung microbiome Randomized trial comparing azithromycin (AZM) treatment with placebo for eight weeks. Bronchoalveolar lavage (BAL) samples were obtained before and after treatment to explore the effects of AZM on microbiome, in the lower airways. 16S rRNA was quantified and sequenced (MiSeq) The amplicons from total 39 samples are barcoded and the barcode is provided in the metadata_complete.txt file.

2016-07-19 | E-GEOD-74396 | biostudies-arrayexpress

PNAs-A15 effects on cervical cancer cells line

Project description:Expression profile of HeLa and C33A cervical cancer cells line treated with PNAs-A15 for 6 hours. PNAs-A15 is peptide nucleic acid of A-repeats length 15 bp that can suppress up-regulated A-repeats containing genes in cervical cancer cells line.

2015-12-23 | GSE76258 | GEO

Membranous Expression of Ectodomain Isoforms of the Epidermal Growth Factor Receptor (EGFR) Predicts Outcome after Chemoradiotherapy of Lymph Node Negative Cervical Cancer

Project description:We compared the prognostic significance of ectodomain isoforms of the epidermal growth factor receptor (EGFR), which lack the tyrosine kinase (TK) domain, with that of the full length receptor and its autophosphorylation status in cervical cancers treated with conventional chemoradiotherapy. We further explored signaling pathways that were correlated with high expression of ectodomain isoforms by gene expression analysis of 110 of the tumors, and validated the results in an independent cohort of 41 tumors. Pathways associated with the expression of ectodomain isoforms were studied by gene expression analysis with Illumina beadarrays in 110 patients and validated in an independent cohort of 41 patients.

2011-07-18 | E-GEOD-29817 | biostudies-arrayexpress

cervical cancer vaginal microbiome

Project description:cervical cancer vaginal microbiome Targeted loci environmental

| PRJNA518153 | ENA